nivobotulinumtoxinA

NivobotulinumtoxinA (MT10109L) is a novel, ready-to-use liquid formulation of botulinum toxin type A (900 kDa complex) developed by Medytox. Unlike traditional botulinum toxin products that are provided as lyophilized powders requiring reconstitution, nivobotulinumtoxinA is a stable liquid formulation with a shelf-life of up to 36 months. It is derived from Clostridium botulinum type A strain Hall and is formulated without human serum albumin or animal-derived proteins, which may reduce the risk of immunogenicity. The drug works by selectively cleaving the synaptosomal-associated protein 25 (SNAP-25) within neuronal cells, thereby inhibiting the release of the neurotransmitter acetylcholine at the neuromuscular junction. This blockade results in temporary muscle paralysis, making it effective for aesthetic and therapeutic indications. It is currently in Phase 3 clinical development for the treatment of moderate-to-severe lateral canthal lines (crow's feet) and glabellar lines (frown lines).

Brand names

Innotox

Other names

nivobotulinumtoxinA-adpvLiquid Botulinum Toxin Type A